Brief: Aeglea BioTherapeutics Q3 basic EPS USD -9.34
09/11/2023 23:01
Nov 9 (Reuters) - Aeglea BioTherapeutics Q3 operating expenses USD 18.337 million. * Q3 income from operations USD -18.337 million * Q3 pretax profit USD -40.104 million * Q3 basic EPS USD -9.34 * Q3 net income USD -40.107 million
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock